[HTML][HTML] Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 …
Background Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
[PDF][PDF] Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 …
J Pavlu - 2019 - helda.helsinki.fi
Background: Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio… - … of Hematology & …, 2019 - search.ebscohost.com
Background: Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
JÅ PavlÅ, M Labopin, R Niittyvuopio, G Socié… - Journal of Hematology …, 2019 - go.gale.com
Background Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio, G Socié… - Journal of Hematology …, 2019 - dabar.srce.hr
Background: Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlu, M Labopin, R Niittyvuopio, G Socie… - Journal of Hematology …, 2019 - hal.univ-lille.fr
Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic
and prognostic landscape of a wide range of hematological malignancies. Its prognostic …
and prognostic landscape of a wide range of hematological malignancies. Its prognostic …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio, G Socié… - Journal of Hematology & …, 2019 - infona.pl
Background Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio, G Socié… - … of Hematology & …, 2019 - europepmc.org
BACKGROUND: Assessment of measurable residual disease (MRD) is rapidly transforming
the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio… - … of Hematology & …, 2019 - repozitorij.mef.unizg.hr
Background: Assessment of measurable residual disease (MRD) is rapidly transforming the
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
therapeutic and prognostic landscape of a wide range of hematological malignancies. Its …
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients …
J Pavlů, M Labopin, R Niittyvuopio, G Socié… - Journal of hematology & …, 2019 - sonar.ch
METHODS In this retrospective registry study, we explored whether measurable residual
disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for acute …
disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for acute …